PubMed · 1991 · 11 citations · 0 references
MedicineCancer BiologyOncologyCarcinogenesisMolecular OncologyNeoplasiaCancer ProgressionChemical CarcinogenesisMalignant NeoplasmsChromium CarcinogenicityMechanisms Of CarcinogenicityMorphological TransformationOsteosarcoma TreatmentPhenotypic AssaysPlasminogen Activator ReleasePlasminogen ActivatorsSoft Agar Colony Formation Assays
The possible carcinogenicity of insoluble chromium (VI) compound, PbCrO4, in human cells has been tested using a nontumorigenic human osteosarcoma cell line (HOS, TE 85). Electron microscopic studies show that PbCrO4 is phagocytosed by HOS cells and accumulates within the vacuoles in the cytoplasm. A number of cell lines have been isolated following multiple treatment of HOS cells with PbCrO4. These cell lines are morphologically different from HOS cells, form anchorage-independent colonies in soft agar and form quickly regressing small tumor nodules in athymic nude mice. The cellular and secreted plasminogen activator (PA) levels of 5 cell lines isolated after PbCrO4 treatment are increased up to 8 fold and up to 10 fold respectively as compared to untreated HOS controls. SDS-PAGE analysis in the presence of copolymerized substrates is consistent with increase in 55 kDa urokinase-type PA (u-PA) and 68 kDa tissue-type PA (t-PA). These results show that PbCrO4 treatment leads to stable phenotypic changes indicative of the transformation of HOS cells.